| mechanism | treatment | Demonstrated benefit and harm | k | | | |
|---|
| antiarrythmic drugs | amiodarone | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ARREST, 1999 | amiodarone vs placebo | survival to hospital admission 1.60 [1.08; 2.37] | | |
| Trial | Treatments | Patients | Method |
|---|
| ARREST, 1999 | intravenous amiodarone 300mg (n=246) vs. placebo (n=258) | Patients with cardiac arrest by ventricular fibrillation (or pulseless ventricular tachycardia) and not resuscitated after receiving three or more precordial shocks | double blind Sample size: 246/258 Primary endpoint: admission to the hospital FU duration: |
|
| antiarrythmic drugs | amiodarone | versus lidocaine No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ALIVE, 2002 | amiodarone vs lidocaine | survival to hospital admission 1.90 [1.16; 3.11] death before hospital admission 0.88 [0.80; 0.97] | | death 0.98 [0.94; 1.02] |
| Trial | Treatments | Patients | Method |
|---|
| ALIVE, 2002 | intravenous amiodarone plus lidocaine placebo (n=180) vs. intravenous lidocaine plus amiodarone placebo (n=167) | out-of-hospital ventricular fibrillation resistant to three shocks, intravenous epinephrine, and a further shock; or recurrent ventricular fibrillation after initially successful defibrillation | double blind Sample size: 180/167 Primary endpoint: admitted alive to hospital FU duration: 1 day |
|
| fibrinolysis | t-pa | versus placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Abu-Laban, 2002 | t-PA vs placebo | | | death 0.99 [0.97; 1.01] Survival to hospital discharge ∞ [NaN; ∞] Return of spontaneous circulation 0.92 [0.57; 1.48] failure to return of spontaneous circulation 1.02 [0.89; 1.18] death before hospital discharge 0.99 [0.97; 1.01] |
| Trial | Treatments | Patients | Method |
|---|
| Abu-Laban, 2002 | t-PA 100mg over a 15-minute period (n=117) vs. placebo (n=116) | Victims of cardiac arrest with pulseless electrical activity for more than one minute and had had no palpable pulse for more than three minutes during resuscitative efforts and at the time of the initiation of the study drug | double blind Parallel groups Sample size: 117/116 Primary endpoint: survival to hospital FU duration: |
|
| fibrinolysis | tenecteplase | versus placebo No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| TROICA, 2008 | tenecteplase vs placebo | | | death 0.87 [0.66; 1.14] Ischemic stroke 0.87 [0.66; 1.14] Symptomatic intracranial hemorrhage 0.87 [0.66; 1.14] Survival to hospital discharge 0.87 [0.66; 1.14] Return of spontaneous circulation 0.87 [0.66; 1.14] failure to return of spontaneous circulation 1.03 [0.97; 1.08] death before hospital discharge 1.03 [0.97; 1.08] | | TICA, 2004 | tenecteplase vs placebo | | | death 0.95 [0.78; 1.17] |
| Trial | Treatments | Patients | Method |
|---|
| TROICA, 2008 | tenecteplase (dose according to estimated
body weight) (n=525) vs. placebo (n=525) | adults with witnessed out-of-hospital cardiac arrest of presumed cardiac origin and with initiation of basic or advanced life support within 10 minutes after collapse | doubel blind Parallel groups Sample size: 525/525 Primary endpoint: 30-day survival FU duration: 30 days | | TICA, 2004 | tenecteplase 50 mg (n=19) vs. placebo (n=16) | All victims of out of hospital cardiac arrest | double blind Parallel groups Sample size: 19/16 Primary endpoint: return of spontaneous circulation FU duration: |
|
| omega-3 fatty acids | fish oil | versus control or placebo No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Raitt , 2006 | fish oil vs placebo | | | all-cause mortality 0.40 [0.13; 1.23] implantable cardioverter defibrillator discharge 1.24 [0.92; 1.69] | | SOFA , 2006 | fish oil vs placebo | | | all-cause mortality 0.57 [0.24; 1.34] implantable cardioverter defibrillator discharge 0.90 [0.70; 1.15] | | Leaf, 2005 | fish oil vs placebo | implantable cardioverter defibrillator discharge 0.74 [0.56; 0.98] | | all-cause mortality 1.09 [0.51; 2.34] |
| Trial | Treatments | Patients | Method |
|---|
| Raitt , 2006 | Fish oil 1.3g (n=100) vs. placebo (olive oil) (n=100) | | double blind parallel group Sample size: 100/100 Primary endpoint: FU duration: | | SOFA , 2006 | Fish oil 0.9g (n=273) vs. placebo (High-oleic sunflower oil) (n=273) | | double blind Parallel groups Sample size: 273/273 Primary endpoint: ICD intervention for VT or VF, or all-cause death. FU duration: 356 days (14-379) | | Leaf, 2005 | Fish oil 2.6g (n=200) vs. placebo (olive oil) (n=202) | | Sample size: 200/202 Primary endpoint: FU duration: |
|
